Indolelactic acid as a potential metabolic biomarker for diagnosing gout

Zhang,Ying; Su,Jiayu; Zhou,Ke; Wang,Shuangshuang; Zhang,Jingwei; Zhang,Tiannan; Liu,Shijia; Lu,Yan

doi:10.3892/etm.2024.12717

Indolelactic acid as a potential metabolic biomarker for diagnosing gout

Authors:
- Ying Zhang
- Jiayu Su
- Ke Zhou
- Shuangshuang Wang
- Jingwei Zhang
- Tiannan Zhang
- Shijia Liu
- Yan Lu
View Affiliations

Affiliations: Department of Pharmacy, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China, School of Life Science and Technology, China Pharmaceutical University, Nanjing, Jiangsu 211198, P.R. China, School of Traditional Chinese Pharmacy, China Pharmaceutical University, Nanjing, Jiangsu 211198, P.R. China, Department of Rheumatology and Immunology, The Affiliated Hospital of Nanjing University of Chinese Medicine, Jiangsu Province Hospital of Chinese Medicine, Nanjing, Jiangsu 210029, P.R. China
Published online on: September 16, 2024 https://doi.org/10.3892/etm.2024.12717
Article Number: 429
Copyright: © Zhang et al. This is an open access article distributed under the terms of Creative Commons Attribution License.

Metrics: Total Views: 0 (Spandidos Publications: | PMC Statistics: )

Metrics: Total PDF Downloads: 0 (Spandidos Publications: | PMC Statistics: )

Cited By (CrossRef): 0 citations Loading Articles...

Abstract

Gout is a heterogeneous disease caused by the deposition of monosodium urate crystals in joints, but its pathogenesis is currently poorly understood. The discovery of novel biomarkers is necessary for the early detection and diagnosis of gout. The present study aimed to characterize the metabolic profile of patients with gout using metabolomics, and to uncover the underlying pathological mechanisms leading to gout development. Serum samples were collected from 49 healthy participants and 47 patients with gout. Using ultra‑high‑performance liquid chromatography Orbitrap Exploris mass spectrometer non‑target metabolomics technology, with a variable importance in the projection >1 and a false discovery rate adjusted P<0.05 was used, while a biomarker panel was screened using receiver operating characteristic (ROC) analysis. The potential differentially expressed markers related to gout were identified by ROC analysis, and the erythrocyte sedimentation rate, uric acid, alanine transaminase, aspartate aminotransferase, creatinine, triglyceride, total cholesterol, high‑density lipoprotein and low‑density lipoprotein levels were significantly different in the group of patients with gout compared with those in healthy individuals. A total of 186 differentially expressed metabolites were identified, with 156 differential metabolites upregulated and 30 downregulated in the patients with gout compared with healthy individuals. Pathway analysis demonstrated that D‑glutamine and D‑glutamate metabolism may serve key roles in gout. Compared with healthy people, the indolelactic acid (ILA) level of patients with gout was significantly higher. ILA may serve as a potential biomarker for the diagnosis of gout and could be used to detect or predict gout progression in the future.

View Figures

View References

1	Dalbeth N, Gosling AL, Gaffo A and Abhishek A: Gout. Lancet. 397:1843–1855. 2021.PubMed/NCBI View Article : Google Scholar
2	Petty HR, Rathod-Mistry T, Menz HB and Roddy E: Foot structure, pain and functional ability in people with gout in primary care: Cross-sectional findings from the clinical assessment study of the foot. J Foot Ankle Res. 12(8)2019.PubMed/NCBI View Article : Google Scholar
3	Singh G, Lingala B and Mithal A: Gout and hyperuricaemia in the USA: Prevalence and trends. Rheumatology (Oxford). 58:2177–2180. 2019.PubMed/NCBI View Article : Google Scholar
4	Pisaniello HL, Lester S, Gonzalez-Chica D, Stocks N, Longo M, Sharplin GR, Dal Grande E, Gill TK, Whittle SL and Hill CL: Gout prevalence and predictors of urate-lowering therapy use: Results from a population-based study. Arthritis Res Ther. 20(143)2018.PubMed/NCBI View Article : Google Scholar
5	Rai SK, Aviña-Zubieta JA, McCormick N, De Vera MA, Shojania K, Sayre EC and Choi HK: The rising prevalence and incidence of gout in British Columbia, Canada: Population-based trends from 2000 to 2012. Semin Arthritis Rheum. 46:451–456. 2017.PubMed/NCBI View Article : Google Scholar
6	Kim JW, Kwak SG, Lee H, Kim SK, Choe JY and Park SH: Prevalence and incidence of gout in Korea: Data from the national health claims database 2007-2015. Rheumatol Int. 37:1499–1506. 2017.PubMed/NCBI View Article : Google Scholar
7	Liu R, Han C, Wu D, Xia X, Gu J, Guan H, Shan Z and Teng W: Prevalence of hyperuricemia and gout in Mainland China from 2000 to 2014: A systematic review and meta-analysis. Biomed Res Int. 2015(762820)2015.PubMed/NCBI View Article : Google Scholar
8	Li X, Gao J and Tao J: Purinergic signaling in the regulation of gout flare and resolution. Front Immunol. 12(785425)2021.PubMed/NCBI View Article : Google Scholar
9	Richette P, Doherty M, Pascual E, Barskova V, Becce F, Castañeda-Sanabria J, Coyfish M, Guillo S, Jansen TL, Janssens H, et al: 2016 Updated EULAR evidence-based recommendations for the management of gout. Ann Rheum Dis. 76:29–42. 2017.PubMed/NCBI View Article : Google Scholar
10	Fraga-Corral M, Carpena M, Garcia-Oliveira P, Pereira AG, Prieto MA and Simal-Gandara J: Analytical metabolomics and applications in health, environmental and food science. Crit Rev Anal Chem. 52:712–734. 2022.PubMed/NCBI View Article : Google Scholar
11	Chen J, Li T, Huang D, Gong W, Tian J, Gao X, Qin X, Du G and Zhou Y: Integrating UHPLC-MS/MS quantitative analysis and exogenous purine supplementation to elucidate the antidepressant mechanism of Chaigui granules by regulating purine metabolism. J Pharm Anal. 13:1562–1576. 2023.PubMed/NCBI View Article : Google Scholar
12	Liu Y, Zhang X, Lin W, Kehriman N, Kuang W and Ling X: Multi-factor combined biomarker screening strategy to rapidly diagnose Alzheimer's disease and evaluate drug effect based on a rat model. J Pharm Anal. 12:627–636. 2022.PubMed/NCBI View Article : Google Scholar
13	Yü TF, Adler M, Bobrow E and Gutman AB: Plasma and urinary amino acids in primary gout, with special reference to glutamine. J Clin Invest. 48:885–894. 1969.PubMed/NCBI View Article : Google Scholar
14	Mahbub MH, Yamaguchi N, Takahashi H, Hase R, Amano H, Kobayashi-Miura M, Kanda H, Fujita Y, Yamamoto H, Yamamoto M, et al: Alteration in plasma free amino acid levels and its association with gout. Environ Health Prev Med. 22(7)2017.PubMed/NCBI View Article : Google Scholar
15	Dalbeth N, Choi HK, Joosten LAB, Khanna PP, Matsuo H, Perez-Ruiz F and Stamp LK: Gout. Nat Rev Dis Primers. 5(69)2019.PubMed/NCBI View Article : Google Scholar
16	Li Q, Wei S, Wu D, Wen C and Zhou J: Urinary metabolomics study of patients with gout using gas chromatography-mass spectrometry. Biomed Res Int. 2018(3461572)2018.PubMed/NCBI View Article : Google Scholar
17	Neogi T, Jansen TLTA, Dalbeth N, Fransen J, Schumacher HR, Berendsen D, Brown M, Choi H, Edwards NL, Janssens HJEM, et al: 2015 Gout classification criteria: An American college of rheumatology/European league against rheumatism collaborative initiative. Ann Rheum Dis. 74:1789–1798. 2015.PubMed/NCBI View Article : Google Scholar
18	Liu H, Xu M, He Q, Wei P, Ke M and Liu S: Untargeted serum metabolomics reveals specific metabolite abnormalities in patients with Crohn's disease. Front Med (Lausanne). 9(814839)2022.PubMed/NCBI View Article : Google Scholar
19	Luan H, Gu W, Li H, Wang Z, Lu L, Ke M, Lu J, Chen W, Lan Z, Xiao Y, et al: Serum metabolomic and lipidomic profiling identifies diagnostic biomarkers for seropositive and seronegative rheumatoid arthritis patients. J Transl Med. 19(500)2021.PubMed/NCBI View Article : Google Scholar
20	Kuo CF, Grainge MJ, Mallen C, Zhang W and Doherty M: Comorbidities in patients with gout prior to and following diagnosis: Case-control study. Ann Rheum Dis. 75:210–217. 2016.PubMed/NCBI View Article : Google Scholar
21	Pagliara AS and Goodman AD: Elevation of plasma glutamate in gout. Its possible role in the pathogenesis of hyperuricemia. N Engl J Med. 281:767–770. 1969.PubMed/NCBI View Article : Google Scholar
22	Servià L, Jové M, Sol J, Pamplona R, Badia M, Montserrat N, Portero-Otin M and Trujillano J: A prospective pilot study using metabolomics discloses specific fatty acid, catecholamine and tryptophan metabolic pathways as possible predictors for a negative outcome after severe trauma. Scand J Trauma Resusc Emerg Med. 27(56)2019.PubMed/NCBI View Article : Google Scholar
23	Wang X, Liu J, Hui X and Song Y: Metabolomics applied to cord serum in preeclampsia newborns: Implications for neonatal outcomes. Front Pediatr. 10(869381)2022.PubMed/NCBI View Article : Google Scholar
24	Liu Z, Jin L, Ma Z, Nizhamuding X, Zeng J, Zhang T, Zhang J, Zhou W and Zhang C: Abnormal kynurenine-pathway metabolites in gout: Biomarkers exploration based on orthogonal partial least squares-discriminant analysis. Clin Chim Acta. 549(117531)2023.PubMed/NCBI View Article : Google Scholar
25	Suo H, Shishir MRI, Wang Q, Wang M, Chen F and Cheng KW: Red wine high-molecular-weight polyphenolic complex ameliorates high-fat diet-induced metabolic dysregulation and perturbation in gut microbiota in mice. J Agric Food Chem. 71:6882–6893. 2023.PubMed/NCBI View Article : Google Scholar
26	Farook VS, Reddivari L, Chittoor G, Puppala S, Arya R, Fowler SP, Hunt KJ, Curran JE, Comuzzie AG, Lehman DM, et al: Metabolites as novel biomarkers for childhood obesity-related traits in Mexican-American children. Pediatr Obes. 10:320–327. 2015.PubMed/NCBI View Article : Google Scholar
27	Huang Y, Xiao M, Ou J, Lv Q, Wei Q, Chen Z, Wu J, Tu L, Jiang Y, Zhang X, et al: Identification of the urine and serum metabolomics signature of gout. Rheumatology (Oxford). 59:2960–2969. 2020.PubMed/NCBI View Article : Google Scholar
28	Liu K, Jia B, Zhou L, Xing L, Wu L, Li Y, Lu J, Zhang L and Guan S: Ultraperformance liquid chromatography coupled with quadrupole time-of-flight mass spectrometry-based metabolomics and lipidomics identify biomarkers for efficacy evaluation of mesalazine in a dextran sulfate sodium-induced ulcerative colitis mouse model. J Proteome Res. 20:1371–1381. 2021.PubMed/NCBI View Article : Google Scholar
29	Zhou B, Lou B, Liu J and She J: Serum metabolite profiles as potential biochemical markers in young adults with community-acquired pneumonia cured by moxifloxacin therapy. Sci Rep. 10(4436)2020.PubMed/NCBI View Article : Google Scholar
30	Popek M, Walter M, Fernando M, Lindner M, Schwab KO and Sass JO: Two inborn errors of metabolism in a newborn: Glutaric aciduria type I combined with isobutyrylglycinuria. Clin Chim Acta. 411:2087–2091. 2010.PubMed/NCBI View Article : Google Scholar
31	Reddy N, Calloni SF, Vernon HJ, Boltshauser E, Huisman TAGM and Soares BP: Neuroimaging findings of organic acidemias and aminoacidopathies. Radiographics. 38:912–931. 2018.PubMed/NCBI View Article : Google Scholar
32	Jaganathan SK and Supriyanto E: Antiproliferative and molecular mechanism of eugenol-induced apoptosis in cancer cells. Molecules. 17:6290–3304. 2012.PubMed/NCBI View Article : Google Scholar
33	Fujisawa S and Murakami Y: Eugenol and its role in chronic diseases. Adv Exp Med Biol. 929:45–66. 2016.PubMed/NCBI View Article : Google Scholar
34	Taleuzzaman M, Jain P, Verma R, Iqbal Z and Mirza MA: Eugenol as a potential drug candidate: A review. Curr Top Med Chem. 21:1804–1815. 2021.PubMed/NCBI View Article : Google Scholar
35	Zhong Z, Huang Y, Huang Q, Zheng S, Huang Z, Deng W and Li T: Serum metabolic profiling analysis of gout patients based on UPLC-Q-TOF/MS. Clin Chim Acta. 515:52–60. 2021.PubMed/NCBI View Article : Google Scholar
36	Chen Z, Huang X, Gao Y, Zeng S and Mao W: Plasma-metabolite-based machine learning is a promising diagnostic approach for esophageal squamous cell carcinoma investigation. J Pharm Anal. 11:505–514. 2021.PubMed/NCBI View Article : Google Scholar